Brokerages Expect Perrigo Company (PRGO) to Post $1.23 Earnings Per Share

Wall Street analysts expect Perrigo Company (NYSE:PRGO) to report earnings per share (EPS) of $1.23 for the current fiscal quarter, according to Zacks. Twelve analysts have issued estimates for Perrigo’s earnings. The lowest EPS estimate is $1.14 and the highest is $1.36. Perrigo reported earnings of $1.24 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 0.8%. The business is scheduled to report its next earnings report on Monday, May 28th.

On average, analysts expect that Perrigo will report full-year earnings of $4.88 per share for the current financial year, with EPS estimates ranging from $4.78 to $4.95. For the next fiscal year, analysts expect that the business will post earnings of $5.37 per share, with EPS estimates ranging from $5.13 to $5.72. Zacks’ EPS averages are an average based on a survey of analysts that cover Perrigo.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Thursday, November 9th. The company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.28. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.17 billion. Perrigo had a negative net margin of 26.28% and a positive return on equity of 11.60%. The company’s revenue was down 2.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.65 earnings per share.

Several research analysts recently weighed in on PRGO shares. Cantor Fitzgerald set a $107.00 price target on shares of Perrigo and gave the stock a “buy” rating in a research report on Monday, December 4th. Jefferies Group set a $71.00 price target on shares of Perrigo and gave the stock a “hold” rating in a research report on Sunday, October 29th. Argus upgraded shares of Perrigo from a “hold” rating to a “buy” rating and set a $93.00 price target for the company in a research report on Friday, December 8th. UBS Group restated a “buy” rating and set a $98.00 price target (up previously from $84.00) on shares of Perrigo in a research report on Thursday, October 5th. Finally, Oppenheimer started coverage on shares of Perrigo in a research report on Thursday, September 7th. They set an “outperform” rating and a $88.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $92.13.

In other news, EVP John Wesolowski sold 450 shares of the stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $83.09, for a total value of $37,390.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 1,051 shares of company stock valued at $89,810. Corporate insiders own 6.90% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. BB&T Securities LLC boosted its position in Perrigo by 0.4% in the 2nd quarter. BB&T Securities LLC now owns 9,062 shares of the company’s stock valued at $684,000 after buying an additional 35 shares during the period. State of Tennessee Treasury Department boosted its position in Perrigo by 0.3% in the 2nd quarter. State of Tennessee Treasury Department now owns 39,214 shares of the company’s stock valued at $2,961,000 after buying an additional 103 shares during the period. Sentry Investment Management LLC boosted its position in Perrigo by 1.1% in the 2nd quarter. Sentry Investment Management LLC now owns 11,028 shares of the company’s stock valued at $833,000 after buying an additional 117 shares during the period. Commonwealth Bank of Australia boosted its position in Perrigo by 13.8% in the 2nd quarter. Commonwealth Bank of Australia now owns 1,455 shares of the company’s stock valued at $108,000 after buying an additional 176 shares during the period. Finally, Nationwide Fund Advisors boosted its position in Perrigo by 0.4% in the 2nd quarter. Nationwide Fund Advisors now owns 55,199 shares of the company’s stock valued at $4,169,000 after buying an additional 200 shares during the period. 83.29% of the stock is owned by hedge funds and other institutional investors.

Shares of Perrigo (NYSE:PRGO) traded up $0.58 during trading on Thursday, hitting $88.51. 606,700 shares of the company’s stock were exchanged, compared to its average volume of 1,663,359. The firm has a market capitalization of $12,250.00, a P/E ratio of -9.66, a P/E/G ratio of 1.85 and a beta of 0.64. Perrigo has a 1-year low of $63.68 and a 1-year high of $91.73. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.24 and a current ratio of 1.72.

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 19th. Stockholders of record on Friday, December 1st were paid a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 30th. This represents a $0.64 annualized dividend and a dividend yield of 0.72%. Perrigo’s dividend payout ratio (DPR) is -6.99%.

TRADEMARK VIOLATION WARNING: “Brokerages Expect Perrigo Company (PRGO) to Post $1.23 Earnings Per Share” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://weekherald.com/2017/12/28/brokerages-expect-perrigo-company-prgo-to-post-1-23-earnings-per-share.html.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Get a free copy of the Zacks research report on Perrigo (PRGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply